Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset Analyses

In the first part of this peer-to-peer discussion at the 2023 Uromigos Live & Unplugged event, Tanya Dorff, MD, City of Hope, and Neeraj Agarwal, MD, University of Utah, discuss how talazoparib has been studied in prostate cancer prior to the TALAPRO-2 study.

The also hit on the goals of the TALAPRO-2 study and the further understandings that subset analyses have provided.

View the other parts of this discussion, including TALAPRO-2: Toxicities and Treatment Duration, How Has TALAPRO-2 Changed the Standard of Care for First-Line mCRPC With HRR Mutations, and Importance of Genomic Testing for Patients With Metastatic Prostate Cancer.